In a patient with unexplained arterial or venous thrombosis, recurrent pregnancy loss, or systemic lupus erythematosus, when should antiphosphatidylserine antibody testing be performed and how should a persistently positive result be managed?

Antiphosphatidylserine Antibody Testing in Clinical Practice

Direct Answer

Antiphosphatidylserine antibody testing is NOT currently recommended as part of standard diagnostic workup for antiphospholipid syndrome, as it is not included in the established classification criteria and guidelines recommend only the three validated tests: lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies. 1

When to Test for Antiphospholipid Antibodies

Testing for antiphospholipid antibodies should be performed in the following clinical scenarios 1:

• Patients with systemic lupus erythematosus or SLE-like disease 1
• Unexplained arterial or venous thrombosis (particularly in younger patients without traditional risk factors) 1
• Recurrent pregnancy loss (≥3 consecutive spontaneous abortions before 10 weeks, or ≥1 unexplained fetal death at or after 10 weeks) 1
• Premature birth before 34 weeks due to eclampsia, severe preeclampsia, or placental insufficiency 1
• Unexplained thrombocytopenia 1
• Livedo reticularis or cardiac valve abnormalities 1

Standard Laboratory Testing Protocol

The triple screening approach is mandatory and includes only these three validated tests 1, 2:

• Lupus anticoagulant (LAC) - requires two phospholipid-dependent clotting assays 1
• Anticardiolipin antibodies (aCL) - IgG and IgM at moderate-to-high titer (>40 units or >99th percentile) 1
• Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG and IgM at moderate-to-high titer (>40 units or >99th percentile) 1

Critical requirement: All positive tests must be confirmed on repeat testing at least 12 weeks apart, as transient positivity occurs frequently with infections and medications 3, 1, 2

Why Antiphosphatidylserine Testing Is Not Standard

The International Society on Thrombosis and Haemostasis explicitly states that other antiphospholipid antibody tests beyond the three criteria tests are not recommended for diagnostic purposes 1. This is despite research showing associations between antiphosphatidylserine antibodies and thrombotic events 4, 5.

Research Context (Not for Clinical Use)

While research studies have shown that antiphosphatidylserine/prothrombin antibodies (aPS/PT) may have predictive value 6, 4, 5, 7:

• One study found aPS/PT positive in 15-16% of recurrent pregnancy loss patients versus 2.9% of controls, with odds ratios of 5.96-7.28 6
• Another study suggested aPS/PT correlates with both arterial and venous thrombosis in SLE patients 4
• Historical data showed antiphosphatidylserine antibodies correlated better with lupus anticoagulant than anticardiolipin 8

However, these tests remain investigational and are not validated for clinical decision-making or treatment initiation 1.

Management of Persistently Positive Standard aPL Tests

Risk Stratification

Triple positivity (LAC + aCL + aβ2GPI of the same isotype) indicates the highest risk for recurrent pregnancy complications and thrombotic events 1, 2. Recent data confirms that:

• Triple-positive patients have the strongest association with thrombosis 3
• Double-positive patients (LAC negative but aCL and aβ2GPI positive with concordant isotype) show 86% meeting clinical APS criteria 3
• Isolated lupus anticoagulant has high predictive value and carries significant weight in classification criteria 3
• Single aCL or aβ2GPI alone show contradictory or poor association with thrombosis 3

Specific Management by Clinical Scenario

For thrombotic APS:

• Lifelong anticoagulation is typically required after first thrombotic event in persistently positive patients 9
• Warfarin has been the traditional standard, though direct oral anticoagulants are being studied 9

For obstetric APS:

• Combination of low-dose aspirin plus prophylactic heparin during pregnancy is standard for patients with recurrent pregnancy loss and persistently positive aPL 6, 9
• Lupus anticoagulant is the strongest risk factor for pregnancy morbidity, with concomitant LA and aβ2GPI positivity showing the highest predictive value 3

Critical Pitfalls to Avoid

• Never diagnose APS based on a single positive test - confirmation after at least 12 weeks is mandatory because transient positivity is frequent 3, 1, 2
• Do not test during acute thrombosis - aβ2GPI titers may decrease at the time of thrombosis due to antibody deposition at the thrombotic site, then increase afterward 3
• Do not test during pregnancy for initial diagnosis - aPL levels fluctuate during pregnancy, with 25% of LA-positive patients becoming negative in second or third trimester due to rising Factor VIII 3
• Repeat testing post-delivery or distant from acute thrombotic event if initial testing occurred during these periods 3
• Lupus anticoagulant testing may be erroneous in patients on anticoagulation therapy 1
• Do not order antiphosphatidylserine or other non-criteria antibody tests for clinical decision-making - they are not validated for diagnosis or treatment decisions 1